Axogen completes acquisition of BioCircuit Technologies

By Public Technologies
  • Axogen completed the acquisition of privately held BioCircuit Technologies, adding the NerveTape device for sutureless peripheral nerve repair.
  • BioCircuit is expected to contribute about $6 million of revenue in Q4 2026.
  • Projected 2027 revenue contribution is about $34 million, not included in Axogen’s latest 2026 outlook of at least 24% growth.
  • Axogen reiterated full-year 2026 gross margin guidance of at least 73%.
  • The company maintained its expectation to be free cash flow positive for full-year 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axogen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610011719PRIMZONEFULLFEED9838295) on October 01, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk